Issue 35, February 17, 2023
America faces daunting and complex healthcare challenges that include and go beyond the current pandemic. In myriad ways, innovative healthcare companies are developing solutions to improve access to care, battle disease, strengthen population health, and meet the needs of underserved communities. This newsletter will offer examples of Healthcare Leadership Council members answering the call. |
|
|
Exploring the Changing Landscape of Cancer Care
The Healthcare Leadership Council hosted a webinar to highlight the commitment to medical research and discovery and the most recent accomplishments of some of its member companies. The webinar, "What's New in Cancer Innovation?", included three panelists from City of Hope, Guardant Health and Novartis.
|
HLC and Confidentiality Coalition Webinar Cybersecurity Playbook for Healthcare
As healthcare becomes increasingly accessible and interconnected, cyber risks pose a threat to the healthcare delivery infrastructure. An expert panel will discuss how healthcare stakeholders respond to cyber attacks, the importance of fostering private-public programs as well as how to strengthen existing privacy and security frameworks to create resilience and trust in healthcare.
Wednesday, February 22, 2023 2:00 p.m. - 3:00 p.m. ET
Speakers: Marilyn Zigmund Luke Vice President AHIP Alicia Bowers Senior Vice President, Enterprise Chief Privacy and Compliance Officer Atrium Health Todd Greene Vice President and Enterprise CISO Atrium Health
Allison Miller Senior Vice President and Chief Information Security Officer UnitedHealth Group
Email questions to Kelly Fernandez at kfernandez@hlc.org |
| Texas Health Resources Broadens Mental Health Services to Meet Community Needs Texas Health Resources, a member of the Healthcare Leadership Council, has expanded its mental health services for adults and adolescents to meet community needs that have increased in part because of the COVID-19 pandemic.
These expanded services include partial hospitalization programs, where patients have access to a doctor, nurse and group therapy for five to six hours a day but are not admitted overnight, and intensive outpatient care, with three-hour group therapy sessions three days a week. They also include targeted programs such as in-person or virtual group therapy sessions for women to discuss issues like postpartum depression, menopause, domestic violence, and sexual abuse; in-person group therapy for adolescents to focus on issues such as depression, anxiety, bullying and abuse; and an adult co-occurring disorder program tailored for those who struggle with both mental health and substance use challenges.
Aliza Hirani, Director of Clinical Services, said "This expansion was vital to provide even more individuals and families with the care and support that they so desperately need to improve their mental health and well-being. Many stressors arose because of the pandemic, such as social isolation, children suddenly doing virtual schooling at home, and adults who lost their jobs or had to adjust to working from home. As a result, repeated studies have shown that more people experienced mental health issues like depression and anxiety and even drank more to try to cope."
|
Baxter Involved in Research to Develop Novel Treatment for Patients with Acute Liver Failure
Baxter International, a member of the Healthcare Leadership Council, is collaborating with Miromatrix Medical to develop a unique therapy for patients with acute liver failure. The treatment will involve a bioengineered liver developed by Miromatrix combined with Baxter's PrisMax system, which is designed to deliver individualized therapies to patients. An Investigational New Drug (IND) application for the therapy has been submitted to the Food and Drug Administration and is believed to be the first-ever IND for a bioengineered organ.
Under the proposed treatment, the bioengineered liver would be connected to Baxter's PrisMax system outside of the patient's body and provide therapeutic support for patients with acute liver failure with, according to the publication Biospace, the end goal of coaxing the patient's own liver back to life.
Brian Tufts, Vice President, Acute Therapies at Baxter, said, "Baxter is focused on promoting continuous innovation to advance our organ support therapies and further elevate care for patients with acute liver failure and other critical conditions. Combining Miromatrix's pioneering bioengineered organ technology with Baxter's expertise in critical care delivery and industry-leading PrisMax system has the potential to transform care for ALF patients." |
|
|
|